ALLMedicine™ B-cell Lymphoma Center
Research & Reviews 7,473 results
https://www.mdedge.com/dermatology/article/255804/dermatopathology/chronic-retiform-purpura-abdomen-and-thighs-fatal-case
Nelson Ugwu, MD, Nour Kibbi, MD et. al.
Jun 28th, 2022 - To the Editor: Intravascular large cell lymphoma (ILCL) is a rare B-cell lymphoma that is defined by the presence of large neoplastic B cells in the lumen of blood vessels. 1 At least 3 variants of ILCL have been described based on case reports and.
https://doi.org/10.1080/16078454.2022.2091197
Hematology (Amsterdam, Netherlands); Zhao J, Zhang W et. al.
Jun 28th, 2022 - To analyse the clinical characteristics and therapeutic response of Chinese patients with primary extranodal diffuse large B-cell lymphoma DLBCL (PE-DLBCL). We analysed the clinical features and outcomes of 197 patients who were newly diagnosed wi...
https://www.mdedge.com/hematology-oncology/article/255765/b-cell-lymphoma/fda-approves-liso-cel-second-line-therapy-lbcl
Sharon Worcester
Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati.
https://doi.org/10.1016/j.clim.2022.109067
Clinical Immunology (Orlando, Fla.); Al-Tamemi S, Alhinai Z et. al.
Jun 25th, 2022 - Severe combined immunodeficiency (SCID) is characterized by severe, early-onset infection in infants. B-cell lymphoma/leukemia (BCL) 10 defects causing SCID have been reported previously in two patients. A seven-month-old female infant was admitte...
https://doi.org/10.1097/MCP.0000000000000879
Current Opinion in Pulmonary Medicine; Semen KO, Bast A
Jun 25th, 2022 - Cellular senescence has been recognized as a promising target in the treatment of many cardiovascular diseases. The pathways involved in the development of senescence share many similarities with pathobiological mechanisms of pulmonary arterial hy...
Guidelines 11 results
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.
Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.
Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...
https://doi.org/10.1111/bjh.15731
British Journal of Haematology; Cwynarski K, Marzolini MAV et. al.
Jan 5th, 2019 - The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.|2019|Cwynarski K,Marzolini MAV,Barrington SF,Follows G,Illidge T,|adverse effects,therapeutic use,chemically induced,diagnostic imaging,t...
https://doi.org/10.1111/bjh.15661
British Journal of Haematology; Fox CP, Phillips EH et. al.
Nov 24th, 2018 - Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.|2018|Fox CP,Phillips EH,Smith J,Linton K,Gallop-Evans E,|diagnosis,therapy,diagnosis,therapy,
https://doi.org/10.1016/j.ijrobp.2017.12.005
International Journal of Radiation Oncology, Biology, Phy... Ng AK, Yahalom J et. al.
Feb 8th, 2018 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will s...
Drugs 11 results see all →
Clinicaltrials.gov 835 results
https://clinicaltrials.gov/ct2/show/NCT01676805
Jun 24th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...
https://clinicaltrials.gov/ct2/show/NCT02911142
Jun 24th, 2022 - Background Kaposi sarcoma herpesvirus (KSHV)-associated primary effusion lymphoma (PEL) is an aggressive B cell neoplasm with clinicopathologic and molecular profiles distinct from other AIDS-related lymphomas. There are no prospective studies on ...
https://clinicaltrials.gov/ct2/show/NCT03484702
Jun 24th, 2022 - This is a study to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell NHL. The study will enroll participants in Europe and Japan with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS; de no...
https://clinicaltrials.gov/ct2/show/NCT00339963
Jun 24th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...
https://clinicaltrials.gov/ct2/show/NCT04739813
Jun 24th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...
News 1,133 results
https://www.mdedge.com/dermatology/article/255804/dermatopathology/chronic-retiform-purpura-abdomen-and-thighs-fatal-case
Nelson Ugwu, MD, Nour Kibbi, MD et. al.
Jun 28th, 2022 - To the Editor: Intravascular large cell lymphoma (ILCL) is a rare B-cell lymphoma that is defined by the presence of large neoplastic B cells in the lumen of blood vessels. 1 At least 3 variants of ILCL have been described based on case reports and.
https://www.mdedge.com/hematology-oncology/article/255765/b-cell-lymphoma/fda-approves-liso-cel-second-line-therapy-lbcl
Sharon Worcester
Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati.
https://www.medscape.com/viewarticle/976230
Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati...
https://www.mdedge.com/hematology-oncology/article/255338/b-cell-lymphoma/novel-gene-therapy-offers-hope-some-lymphomas
Heidi Splete
Jun 9th, 2022 - Lisocabtagene maraleucel, a novel chimeric antigen receptor (CAR) T-cell product, evoked a clinical response in patients with relapsed or refractory large B-cell lymphoma in a pilot study presented at the annual meeting of the American Society of.
https://www.mdedge.com/hematology-oncology/article/255306/b-cell-lymphoma/glofitamab-prevails-against-r/r-dlbcl
Heidi Splete
Jun 9th, 2022 - Approximately half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) treated with glofitamab showed clinical response, based on phase 2 data from 154 adults. “We know that relapsed diffuse large B-cell lymphoma has a pa.